Target
NKG2A
6 abstracts
Abstract
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).Org: Centre Hospitalier Intercommunal de Créteil, Cancer Center of Kansas, University of Colorado Anschutz Medical Center,
Abstract
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.Org: Richard L Roudebush VA Medical Center,
Abstract
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.Org: Owkin France, Centre Leon Berad,
Abstract
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).Org: Virginia Cancer Specialists, AstraZeneca, Bloomberg–Kimmel Institute for Cancer Immunotherapy,
Abstract
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).Org: Gustave Roussy and Paris Saclay University, Villejuif, France, Faculty of Medicine, Cairo University, Villejuif / Kremlin-Bicêtre, France, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Cancer Center at Brown University,